vs
Amphastar Pharmaceuticals, Inc.（AMPH）とPacira BioSciences, Inc.（PCRX）の財務データ比較。上の社名をクリックして会社を切り替えられます
Pacira BioSciences, Inc.の直近四半期売上が大きい（$196.9M vs $183.1M、Amphastar Pharmaceuticals, Inc.の約1.1倍）。Pacira BioSciences, Inc.の前年同期比売上増加率が高い（5.1% vs -1.8%）。Pacira BioSciences, Inc.の直近四半期フリーキャッシュフローが多い（$43.5M vs $24.6M）。過去8四半期でPacira BioSciences, Inc.の売上複合成長率が高い（8.5% vs 3.2%）
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
Pacira BioSciences社は非オピオイド系疼痛管理ソリューションの開発・商業化に特化した専門製薬企業で、主に米国の病院や外来手術センターなどの医療機関に術後鎮痛向け製品を提供し、一部海外市場への展開も進めています。
AMPH vs PCRX — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $183.1M | $196.9M |
| 純利益 | $24.4M | — |
| 粗利率 | 46.8% | 79.5% |
| 営業利益率 | 19.4% | 1.2% |
| 純利益率 | 13.3% | — |
| 売上前年比 | -1.8% | 5.1% |
| 純利益前年比 | -35.7% | — |
| EPS（希薄化後） | $0.51 | $0.05 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $183.1M | $196.9M | ||
| Q3 25 | $191.8M | $179.5M | ||
| Q2 25 | $174.4M | $181.1M | ||
| Q1 25 | $170.5M | $168.9M | ||
| Q4 24 | $186.5M | $187.3M | ||
| Q3 24 | $191.2M | $168.6M | ||
| Q2 24 | $182.4M | $178.0M | ||
| Q1 24 | $171.8M | $167.1M |
| Q4 25 | $24.4M | — | ||
| Q3 25 | $17.4M | $5.4M | ||
| Q2 25 | $31.0M | $-4.8M | ||
| Q1 25 | $25.3M | $4.8M | ||
| Q4 24 | $38.0M | — | ||
| Q3 24 | $40.4M | $-143.5M | ||
| Q2 24 | $37.9M | $18.9M | ||
| Q1 24 | $43.2M | $9.0M |
| Q4 25 | 46.8% | 79.5% | ||
| Q3 25 | 51.4% | 80.9% | ||
| Q2 25 | 49.6% | 77.4% | ||
| Q1 25 | 50.0% | 79.7% | ||
| Q4 24 | 46.5% | 78.7% | ||
| Q3 24 | 53.3% | 76.9% | ||
| Q2 24 | 52.2% | 75.1% | ||
| Q1 24 | 52.4% | 71.6% |
| Q4 25 | 19.4% | 1.2% | ||
| Q3 25 | 13.2% | 3.5% | ||
| Q2 25 | 24.2% | 4.7% | ||
| Q1 25 | 21.9% | 1.2% | ||
| Q4 24 | 24.2% | 13.2% | ||
| Q3 24 | 29.8% | -82.8% | ||
| Q2 24 | 30.3% | 15.9% | ||
| Q1 24 | 27.9% | 7.9% |
| Q4 25 | 13.3% | — | ||
| Q3 25 | 9.0% | 3.0% | ||
| Q2 25 | 17.8% | -2.7% | ||
| Q1 25 | 14.8% | 2.8% | ||
| Q4 24 | 20.4% | — | ||
| Q3 24 | 21.1% | -85.1% | ||
| Q2 24 | 20.8% | 10.6% | ||
| Q1 24 | 25.1% | 5.4% |
| Q4 25 | $0.51 | $0.05 | ||
| Q3 25 | $0.37 | $0.12 | ||
| Q2 25 | $0.64 | $-0.11 | ||
| Q1 25 | $0.51 | $0.10 | ||
| Q4 24 | $0.74 | $0.38 | ||
| Q3 24 | $0.78 | $-3.11 | ||
| Q2 24 | $0.73 | $0.39 | ||
| Q1 24 | $0.81 | $0.19 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | $238.4M |
| 総負債低いほど良い | $608.7M | $372.2M |
| 株主資本純資産 | $788.8M | $693.1M |
| 総資産 | $1.6B | $1.3B |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | 0.54× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $282.8M | $238.4M | ||
| Q3 25 | $276.2M | $246.3M | ||
| Q2 25 | $231.8M | $445.9M | ||
| Q1 25 | $236.9M | $493.6M | ||
| Q4 24 | $221.6M | $484.6M | ||
| Q3 24 | $250.5M | $453.8M | ||
| Q2 24 | $217.8M | $404.2M | ||
| Q1 24 | $289.6M | $325.9M |
| Q4 25 | $608.7M | $372.2M | ||
| Q3 25 | $608.6M | $376.7M | ||
| Q2 25 | $607.7M | $580.5M | ||
| Q1 25 | $603.9M | $583.4M | ||
| Q4 24 | $601.6M | $585.3M | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $693.1M | ||
| Q3 25 | $776.7M | $727.2M | ||
| Q2 25 | $757.5M | $757.8M | ||
| Q1 25 | $751.3M | $798.5M | ||
| Q4 24 | $732.3M | $778.3M | ||
| Q3 24 | $727.7M | $749.6M | ||
| Q2 24 | $713.3M | $879.3M | ||
| Q1 24 | $672.4M | $892.2M |
| Q4 25 | $1.6B | $1.3B | ||
| Q3 25 | $1.7B | $1.3B | ||
| Q2 25 | $1.6B | $1.5B | ||
| Q1 25 | $1.6B | $1.6B | ||
| Q4 24 | $1.6B | $1.6B | ||
| Q3 24 | $1.5B | $1.5B | ||
| Q2 24 | $1.5B | $1.6B | ||
| Q1 24 | $1.6B | $1.6B |
| Q4 25 | 0.77× | 0.54× | ||
| Q3 25 | 0.78× | 0.52× | ||
| Q2 25 | 0.80× | 0.77× | ||
| Q1 25 | 0.80× | 0.73× | ||
| Q4 24 | 0.82× | 0.75× | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | $43.7M |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | $43.5M |
| FCFマージンFCF / 売上 | 13.4% | 22.1% |
| 設備投資強度設備投資 / 売上 | 4.5% | 0.1% |
| キャッシュ転換率営業CF / 純利益 | 1.35× | — |
| 直近12ヶ月FCF直近4四半期 | $121.2M | $136.7M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $32.9M | $43.7M | ||
| Q3 25 | $52.6M | $60.8M | ||
| Q2 25 | $35.6M | $12.0M | ||
| Q1 25 | $35.1M | $35.5M | ||
| Q4 24 | $29.0M | $33.1M | ||
| Q3 24 | $60.0M | $53.9M | ||
| Q2 24 | $69.1M | $53.2M | ||
| Q1 24 | $55.3M | $49.1M |
| Q4 25 | $24.6M | $43.5M | ||
| Q3 25 | $47.2M | $57.0M | ||
| Q2 25 | $25.0M | $9.3M | ||
| Q1 25 | $24.4M | $26.9M | ||
| Q4 24 | $16.6M | $31.0M | ||
| Q3 24 | $46.2M | $49.8M | ||
| Q2 24 | $63.1M | $51.6M | ||
| Q1 24 | $46.5M | $46.3M |
| Q4 25 | 13.4% | 22.1% | ||
| Q3 25 | 24.6% | 31.7% | ||
| Q2 25 | 14.3% | 5.1% | ||
| Q1 25 | 14.3% | 15.9% | ||
| Q4 24 | 8.9% | 16.6% | ||
| Q3 24 | 24.1% | 29.6% | ||
| Q2 24 | 34.6% | 29.0% | ||
| Q1 24 | 27.1% | 27.7% |
| Q4 25 | 4.5% | 0.1% | ||
| Q3 25 | 2.8% | 2.2% | ||
| Q2 25 | 6.1% | 1.5% | ||
| Q1 25 | 6.3% | 5.1% | ||
| Q4 24 | 6.7% | 1.1% | ||
| Q3 24 | 7.2% | 2.4% | ||
| Q2 24 | 3.3% | 0.9% | ||
| Q1 24 | 5.1% | 1.7% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | 11.20× | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | 7.37× | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | 2.82× | ||
| Q1 24 | 1.28× | 5.47× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
